Iguratimod for the treatment of rheumatoid arthritis in Japan

References

• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19
   PubMed Web of Science ®Google Scholar
• Rasheed Z, Haqqi TM. Update on Targets of Biologic Therapies for Rheumatoid Arthritis. Curr Rheumatol Rev 2008;4:246
   PubMedGoogle Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11
   PubMed Web of Science ®Google Scholar
• Panayi G.S. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology Oxford 2005;44(Suppl 2):ii3-7
   PubMed Web of Science ®Google Scholar
• Benoist C, Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2000;2:90-4
   PubMedGoogle Scholar
• Wang Q, Ma Y, Liu D, et al. The roles of B cells and their interactions with fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. Int Arch Allergy Immunol 2011;155:205-11
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22
   PubMedGoogle Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86
   PubMed Web of Science ®Google Scholar
• Inaba T, Tanaka K, Takeno R, et al. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromene. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models. Chem Pharm Bull 2000;48:131-9
   PubMed Web of Science ®Google Scholar
• Tanaka K. Iguratimod (T-614): a novel disease modifying anti-rheumatic drug. Rheumatology Reports 2009;1:e4
   Google Scholar
• Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc) 2012;48:577-86
   PubMed Web of Science ®Google Scholar
• Japan College of Rheumatology. Guidelines for the management of rheumatoid arthritis, 2014. Tokyo: Medical Review 2014; in Japanese
   Google Scholar
• van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20
   PubMed Web of Science ®Google Scholar
• Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824-35
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18
   PubMed Web of Science ®Google Scholar
• Tanaka K, Makino S, Shimotori T, et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4’-1-benzopyran-4-one. 2nd communication., effect on the arachidonic acid cascades. Arzneimittelforschung 1992;42:945-50
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kawasaki H, Kurata K, et al. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995;67:305-14
   PubMedGoogle Scholar
• Tanaka K, Aikawa Y, Kawasaki H, et al. Pharmacological studies on 3-formylamino-7- methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), 4th communication., Inhibitory effects on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn 1992;15:649-55
   PubMedGoogle Scholar
• Kohno M, Aikawa Y, Tsubouchi Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-a induced cytokine production and nuclear factor-κB activation in cultured human synovial cells. J Rheumatol 2001;28:2591-6
   PubMed Web of Science ®Google Scholar
• Aikawa Y, Yamamoto M, Yamamoto T, et al. An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α -stimulated THP-1 cells without interfering with the IκBα degradation. Inflamm Res 2002;51:188-94
   PubMed Web of Science ®Google Scholar
• Muller-Ladner U, Gay RE, Gay S. Role of nuclear factor kappaB in synovial inflammation. Curr Rherumatol Rep 2002;4:201-7
   PubMedGoogle Scholar
• Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008;10:212
   PubMedGoogle Scholar
• Kawakami A, Tsuboi M, Urayama S, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecules, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999;133:566-74
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yamamoto T, Aikawa Y, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted in SCID mice. Rheumatology Oxford 2003;42:1365-71
   PubMed Web of Science ®Google Scholar
• Luo Q, Sun Y, Liu W, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol 2013;191:4969-78
   PubMed Web of Science ®Google Scholar
• Saitoh T, Yamaguchi T. Clinical trials of T-614 in the patients with rheumatoid arthritis. Rheumati-ka 2000.23:571-4 in Japanese Available from: www.info. pmda.go.jp/shinyaku/P201200067/index.html
   Google Scholar
• Hara M, Abe T, Sugawara S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 2007;17:1-9
   PubMedGoogle Scholar
• Fries JF, Bloch DA, Sharp JT, et al. Assessment of radiologic progression in rheumatoid arthritis. Arthritis Rheum 1986;29:1-9
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65
   PubMed Web of Science ®Google Scholar
• Safety review. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/98/20905_ARAVA_MEDR_P2.PDF
   Google Scholar
• Ishiguro N, Yamamoto K, Katayama K, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 2013;23:430-9
   PubMed Web of Science ®Google Scholar
• Hara M, Ishiguro N, Katayama K, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 2014;24:410-18
   PubMed Web of Science ®Google Scholar
• Wells G.A, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol 1993;20:557-60
   PubMed Web of Science ®Google Scholar
• Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 2007;17:10-16
   PubMedGoogle Scholar
• Okamura K, Yonemoto Y, Okura C, et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol 2015;25(2):235-40
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 2002;137:726-33
   PubMed Web of Science ®Google Scholar
• Japan College of Rheumatology. Guidelines for the treatment with methotrexate (MTX) in the management of rheumatoid arthritis, 2011. Tokyo: Yodosya 2011; in Japanese
   Google Scholar
• Murao H, Omatsu N, Aikawa Y, et al. Iguratimod, a disease-modifying antirheumatic drug, suppressed osteoclast differentiation in vitro. In: abstract of the 2008 APLAR. Int J Rheum Dis 2008;11(Suppl 1):A112
   Google Scholar